LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.11M | -27.54M | -24.08M | -28.48M | -41.87M |
| Total Depreciation and Amortization | 467.00K | 373.00K | 479.00K | 546.00K | 612.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 720.00K | 3.76M | 1.43M | 2.51M | 4.85M |
| Change in Net Operating Assets | 4.38M | -6.51M | -6.22M | -7.64M | -3.88M |
| Cash from Operations | -19.54M | -29.92M | -28.39M | -33.07M | -40.28M |
| Capital Expenditure | -23.00K | -24.00K | -7.00K | -231.00K | -731.00K |
| Sale of Property, Plant, and Equipment | 88.00K | 94.00K | 92.00K | 89.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.41M | -7.25M | -24.57M | -24.45M | -16.91M |
| Cash from Investing | 12.48M | -7.18M | -24.48M | -24.60M | -17.64M |
| Total Debt Issued | 0.00 | 0.00 | 24.00K | 13.00K | 0.00 |
| Total Debt Repaid | -596.00K | 346.00K | 210.00K | 76.00K | 0.00 |
| Issuance of Common Stock | 27.00K | 27.00K | 25.00K | 8.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -569.00K | 373.00K | 259.00K | 97.00K | 0.00 |
| Foreign Exchange rate Adjustments | -1.58M | 1.03M | 92.00K | 154.00K | 1.82M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.22M | -35.70M | -52.52M | -57.42M | -56.10M |